{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T16:44:55Z","timestamp":1648572295677},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.pcad.2007.08.003","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T14:52:33Z","timestamp":1196779953000},"page":"167-180","source":"Crossref","is-referenced-by-count":2,"title":["The Use of Antithrombotics for Acute Coronary Syndromes in the Emergency Department: Considerations and Impact"],"prefix":"10.1016","volume":"50","author":[{"given":"Debabrata","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim A.","family":"Eagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2007.08.003_bib1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.CIR.0000134791.68010.FA","volume":"110","author":"Antman","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.08.003_bib2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0735-1097(02)02336-7","volume":"40","author":"Antman","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.08.003_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.292.1.45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non\u2013ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. Primary results of the SYNERGY randomized trial","volume":"292","author":"The SYNERGY Trial Investigators","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2007.08.003_bib4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(01)05775-0","article-title":"Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASENT-3 randomised trial in acute myocardial infarction","volume":"358","author":"The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.08.003_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.0000081659.72985.A8","volume":"108","author":"Wallentin","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.08.003_bib6","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction","volume":"354","author":"Antman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.08.003_bib7","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1161\/hc3101.093866","article-title":"Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin. Second trial of Heparin and Aspirin Reperfusion Therapy (HART II)","volume":"104","author":"Ross","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.08.003_bib8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0195-668X(03)00006-X","article-title":"Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction\u2014the ASSENT Plus study","volume":"24","author":"Wallentin","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2007.08.003_bib9","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1161\/01.CIR.0000013402.34759.46","article-title":"Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction. Results of the ENTIRE\u2014Thrombolysis in Myocardial Infarction (TIMI) 23 Trial","volume":"105","author":"Antman","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.08.003_bib10","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0735-1097(03)01040-4","article-title":"The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI). A randomized trial","volume":"42","author":"Cohen","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.08.003_bib11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2007.08.003_bib12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.08.003_bib13","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non\u2013Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.08.003_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low-molecular-weight heparin during instability in coronary artery disease","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.08.003_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","article-title":"Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study","volume":"96","author":"Klein","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.08.003_bib16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0140-6736(99)07350-X","article-title":"Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study","volume":"354","author":"FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.08.003_bib17","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/euhj.1999.1879","volume":"20","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2007.08.003_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.292.1.55","article-title":"Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non\u2013ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. A randomized controlled trial","volume":"292","author":"Blazing","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2007.08.003_bib19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/mhj.2002.126115","article-title":"Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non\u2013ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study","volume":"144","author":"Cohen","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2007.08.003_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.CIR.0000050144.67910.13","article-title":"Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non\u2013ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb\/IIIa inhibitor eptifibatide","volume":"107","author":"Goodman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.08.003_bib21","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1053\/euhj.2002.3257","article-title":"Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes","volume":"23","author":"James","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2007.08.003_bib22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0002-8703(03)00179-0","article-title":"Enoxaparin versus tinzaparin in non\u2013ST-segment elevation acute coronary syndromes: The EVET trial","volume":"146","author":"Michalis","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2007.08.003_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0735-1097(02)02631-1","article-title":"Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary interventions. Results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study","volume":"41","author":"Bhatt","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.08.003_bib24","first-page":"272","article-title":"Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention","volume":"13","author":"Kereiakes","year":"2001","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.pcad.2007.08.003_bib25","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0002-8703(03)00165-0","article-title":"Combining enoxaparin and glycoprotein IIb\/IIIa antagonists for the treatment of acute coronary syndromes: Final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study","volume":"146","author":"Ferguson","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2007.08.003_bib26","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.08.003_bib27","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.08.003_bib28","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina\/non\u2013Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.08.003_bib29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0735-1097(00)00808-1","article-title":"Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events","volume":"36","author":"Goodman","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.08.003_bib30","doi-asserted-by":"crossref","first-page":"3L","DOI":"10.1016\/S0002-9149(98)00105-2","article-title":"Low-molecular-weight heparins: Pharmacologic profile and product differentiation","volume":"82","author":"Fareed","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2007.08.003_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ahj.2004.09.028","article-title":"Enoxaparin versus tinzaparin in non\u2013ST-segment elevation acute coronary syndromes: Results of the enoxaparin versus tinzaparin (EVET) trial at 6 months","volume":"150","author":"Katsouras","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2007.08.003_bib32","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular weight heparin. The Seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2007.08.003_bib33","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2003.04811.x","article-title":"Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers","volume":"124","author":"Bijesterveld","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pcad.2007.08.003_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jama.292.1.89","article-title":"Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non\u2013ST-segment elevation acute coronary syndromes. A systematic overview","volume":"292","author":"Petersen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2007.08.003_bib35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2165\/00019053-200220140-00003","article-title":"Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome","volume":"20","author":"Brosa","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.pcad.2007.08.003_bib36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0002-8703(00)90085-1","article-title":"Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?","volume":"139","author":"O'Brien","year":"2000","journal-title":"Am Heart J"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062007000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062007000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T12:26:48Z","timestamp":1546432008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062007000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0033062007000771"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2007.08.003","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}